Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T

Clinical Advances in Hematology & Oncology June 2013, Volume 11, Issue 6   Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW Background¬† […]

Commentary: Romidepsin for Previously Treated Patients With Peripheral or Aggressive T-Cell Lymphomas

Romidepsin Induces Durable Responses in Relapsed/Refractory PTCL Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in […]